Anke Van der Perren

Marianne S. Carlon^*,1, 

Jaan Toelen^*,2, 

Marina Mori da Cunha², 

Dragana Vidović¹, 

Anke Van der Perren³, 

Steffi Mayer², 

Lourenço Sbragia², 

Johan Nuyts⁴, 

Uwe Himmelreich⁵, 

Zeger Debyser¹, 

Jan Deprest² 

¹Molecular Virology and Gene Therapy, KU Leuven, 

²Department of Woman and Child, KU Leuven, 

³Neurobiology and Gene Therapy, KU Leuven, 

⁴Division of Nuclear Medicine, KU Leuven, 

⁵Biomedical NMR Unit/ MoSAIC, KU Leuven 

Anke Van der Perren¹, 

Cindy Casteels², 

Koen Van Laere², 

Rik Gijsbers^3,4, 

Chris Van den Haute^1,4, 

Veerle Baekelandt¹ 

¹Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, 

²Division of Nuclear Medicine, Leuven University Hospital - KU Leuven, 

³Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 

⁴Leuven Viral Vector Core, KU Leuven